Stock Events

Stock Events

Bioxytran 

$0.020200
4
-$0.00-4.27% Thursday 20:00

Statistics

Day High
0.0211
Day Low
0.0202
52W High
0.0949
52W Low
0.0201
Volume
5,028
Avg. Volume
85,671
Mkt Cap
2.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0.01
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.12MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops drugs for life-threatening diseases, including those in areas where Bioxytran operates, making them direct competitors in the biotech and pharmaceutical space.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech firm focusing on human therapeutics, with products that could compete with Bioxytran's treatments in various therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of medicines for serious medical conditions, potentially overlapping with Bioxytran's market.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is known for creating novel therapies for treating serious diseases, which could include competitive products in the same domain as Bioxytran.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, and while their main focus differs, their expansion into new therapeutic areas could make them a competitor to Bioxytran.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, potentially in competition with Bioxytran's products.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, and their innovative approach to drug development could position them as competitors in the same therapeutic areas as Bioxytran.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in various therapeutic areas, including those targeted by Bioxytran, making them a broad competitor.

About

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Show more...
CEO
David Platt
Employees
2
Country
United States
ISIN
US09075D1028

Listings

OTC Link
US
BIXT

0 Comments

Share your thoughts

FAQ

What is Bioxytran stock price today?▼
The current price of BIXT is $0.02 USD — it has decreased by -4.27% in the past 24 hours. Watch Bioxytran stock price performance more closely on the chart.
What is Bioxytran stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Bioxytran stocks are traded under the ticker BIXT.
Is Bioxytran stock price growing?▼
BIXT stock has fallen by -10.62% compared to the previous week, the month change is a -8.18% fall, over the last year Bioxytran has showed a -73.75% decrease.
What is Bioxytran market cap?▼
Today Bioxytran has the market capitalization of 2.29M
What is Bioxytran revenue for the last year?▼
Bioxytran revenue for the last year amounts to 0 USD.
What is Bioxytran net income for the last year?▼
BIXT net income for the last year is -2.12M USD.
How many employees does Bioxytran have?▼
As of September 04, 2026, the company has 2 employees.
In which sector is Bioxytran located?▼
Bioxytran operates in the Health & Wellness sector.
When did Bioxytran complete a stock split?▼
The last stock split for Bioxytran was on August 22, 2018 with a ratio of 1:30.
Where is Bioxytran headquartered?▼
Bioxytran is headquartered in Needham, United States.